Equillium Business Summary

Equillium, Inc. (EQ) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaboration and licensing agreements, though it is currently transitioning its financial model toward capital market-driven funding following the 2025 termination of its itolizumab partnership with Biocon. The company's primary business segments are centered on the development of novel immunomodulatory therapies, specifically its lead program EQ504—a multi-modal aryl hydrocarbon receptor (AhR) modulator targeting ulcerative colitis and inflammatory lung diseases—and its proprietary Multi-Cytokine Inhibitor Platform. Equillium competes directly with specialized immunology firms such as Kyverna Therapeutics, Aura Biosciences, and Invivyd, positioning itself as a precision-focused developer of non-immunosuppressive treatments that restore immune balance rather than inducing broad systemic suppression. The company was co-founded by Daniel M. Bradbury, Bruce D. Steel, and Dr. Stephen Connelly, leveraging a high-pedigree leadership team with deep roots in the San Diego biotech ecosystem. Bruce Steel serves as Chief Executive Officer, bringing a background from BioMed Ventures, while Dr. Stephen Connelly serves as President and Chief Scientific Officer, having previously held key roles at The Scripps Research Institute and aTyr Pharma. The executive suite is rounded out by CFO Jason A. Keyes and COO Christine Zedelmayer, with Daniel Bradbury—the former CEO of Amylin Pharmaceuticals—serving as Chairman of the Board. Equillium is backed by a sophisticated investor syndicate that includes Janus Henderson Investors, ADAR1 Capital Management, and Adage Capital Partners, which recently anchored a $50 million private placement to extend the company's operational runway through 2027.